Could psychedelics open new doors for science and business?: psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being
Psychedelic drugs have a history clouded by stigma, but a new wave of clinical research could change how they're perceived and used. Today, a psychedelic renaissance points to potential uses of such drugs in the fields of psychiatry, mental health, and well-being. Some companies have seized upo...
Gespeichert in:
| Beteiligte Personen: | , , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
[Cambridge, Massachusetts]
MIT Sloan Management Review
2022
|
| Ausgabe: | [First edition]. |
| Schlagwörter: | |
| Links: | https://learning.oreilly.com/library/view/-/53863MIT64230/?ar |
| Zusammenfassung: | Psychedelic drugs have a history clouded by stigma, but a new wave of clinical research could change how they're perceived and used. Today, a psychedelic renaissance points to potential uses of such drugs in the fields of psychiatry, mental health, and well-being. Some companies have seized upon psychedelics' potential to treat psychological conditions and spur creativity and are making business investments that they hope will pay off in breakthroughs that improve people's lives. |
| Beschreibung: | "Reprint 64230." |
| Umfang: | 1 Online-Ressource (5 Seiten) |
Internformat
MARC
| LEADER | 00000cam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-30-ORH-08365819X | ||
| 003 | DE-627-1 | ||
| 005 | 20240228121854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230111s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627-1)08365819X | ||
| 035 | |a (DE-599)KEP08365819X | ||
| 035 | |a (ORHE)53863MIT64230 | ||
| 035 | |a (DE-627-1)08365819X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | |a 615.7/883 |2 23/eng/20221213 | |
| 100 | 1 | |a Meister, Alyson |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Could psychedelics open new doors for science and business? |b psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being |c Alyson Meister, Kaja Oppegaard, Eric Grotefeld, Cyril Bouquet |
| 250 | |a [First edition]. | ||
| 264 | 1 | |a [Cambridge, Massachusetts] |b MIT Sloan Management Review |c 2022 | |
| 300 | |a 1 Online-Ressource (5 Seiten) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a "Reprint 64230." | ||
| 520 | |a Psychedelic drugs have a history clouded by stigma, but a new wave of clinical research could change how they're perceived and used. Today, a psychedelic renaissance points to potential uses of such drugs in the fields of psychiatry, mental health, and well-being. Some companies have seized upon psychedelics' potential to treat psychological conditions and spur creativity and are making business investments that they hope will pay off in breakthroughs that improve people's lives. | ||
| 650 | 0 | |a Hallucinogenic drugs |x Therapeutic use | |
| 650 | 4 | |a Hallucinogènes ; Emploi en thérapeutique | |
| 650 | 4 | |a Hallucinogenic drugs ; Therapeutic use | |
| 700 | 1 | |a Oppegaard, Kaja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grotefeld, Eric |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bouquet, Cyril |e VerfasserIn |4 aut | |
| 966 | 4 | 0 | |l DE-91 |p ZDB-30-ORH |q TUM_PDA_ORH |u https://learning.oreilly.com/library/view/-/53863MIT64230/?ar |m X:ORHE |x Aggregator |z lizenzpflichtig |3 Volltext |
| 912 | |a ZDB-30-ORH | ||
| 912 | |a ZDB-30-ORH | ||
| 951 | |a BO | ||
| 912 | |a ZDB-30-ORH | ||
| 049 | |a DE-91 | ||
Datensatz im Suchindex
| DE-BY-TUM_katkey | ZDB-30-ORH-08365819X |
|---|---|
| _version_ | 1821494816513458176 |
| adam_text | |
| any_adam_object | |
| author | Meister, Alyson Oppegaard, Kaja Grotefeld, Eric Bouquet, Cyril |
| author_facet | Meister, Alyson Oppegaard, Kaja Grotefeld, Eric Bouquet, Cyril |
| author_role | aut aut aut aut |
| author_sort | Meister, Alyson |
| author_variant | a m am k o ko e g eg c b cb |
| building | Verbundindex |
| bvnumber | localTUM |
| collection | ZDB-30-ORH |
| ctrlnum | (DE-627-1)08365819X (DE-599)KEP08365819X (ORHE)53863MIT64230 |
| dewey-full | 615.7/883 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7/883 |
| dewey-search | 615.7/883 |
| dewey-sort | 3615.7 3883 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | [First edition]. |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02098cam a22004092 4500</leader><controlfield tag="001">ZDB-30-ORH-08365819X</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20240228121854.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230111s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)08365819X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP08365819X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ORHE)53863MIT64230</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)08365819X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.7/883</subfield><subfield code="2">23/eng/20221213</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Meister, Alyson</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Could psychedelics open new doors for science and business?</subfield><subfield code="b">psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being</subfield><subfield code="c">Alyson Meister, Kaja Oppegaard, Eric Grotefeld, Cyril Bouquet</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">[First edition].</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Cambridge, Massachusetts]</subfield><subfield code="b">MIT Sloan Management Review</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (5 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"Reprint 64230."</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Psychedelic drugs have a history clouded by stigma, but a new wave of clinical research could change how they're perceived and used. Today, a psychedelic renaissance points to potential uses of such drugs in the fields of psychiatry, mental health, and well-being. Some companies have seized upon psychedelics' potential to treat psychological conditions and spur creativity and are making business investments that they hope will pay off in breakthroughs that improve people's lives.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Hallucinogenic drugs</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hallucinogènes ; Emploi en thérapeutique</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hallucinogenic drugs ; Therapeutic use</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oppegaard, Kaja</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grotefeld, Eric</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bouquet, Cyril</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="966" ind1="4" ind2="0"><subfield code="l">DE-91</subfield><subfield code="p">ZDB-30-ORH</subfield><subfield code="q">TUM_PDA_ORH</subfield><subfield code="u">https://learning.oreilly.com/library/view/-/53863MIT64230/?ar</subfield><subfield code="m">X:ORHE</subfield><subfield code="x">Aggregator</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-ORH</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-ORH</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-30-ORH</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield></record></collection> |
| id | ZDB-30-ORH-08365819X |
| illustrated | Not Illustrated |
| indexdate | 2025-01-17T11:20:23Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (5 Seiten) |
| psigel | ZDB-30-ORH TUM_PDA_ORH ZDB-30-ORH |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | MIT Sloan Management Review |
| record_format | marc |
| spelling | Meister, Alyson VerfasserIn aut Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being Alyson Meister, Kaja Oppegaard, Eric Grotefeld, Cyril Bouquet [First edition]. [Cambridge, Massachusetts] MIT Sloan Management Review 2022 1 Online-Ressource (5 Seiten) Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier "Reprint 64230." Psychedelic drugs have a history clouded by stigma, but a new wave of clinical research could change how they're perceived and used. Today, a psychedelic renaissance points to potential uses of such drugs in the fields of psychiatry, mental health, and well-being. Some companies have seized upon psychedelics' potential to treat psychological conditions and spur creativity and are making business investments that they hope will pay off in breakthroughs that improve people's lives. Hallucinogenic drugs Therapeutic use Hallucinogènes ; Emploi en thérapeutique Hallucinogenic drugs ; Therapeutic use Oppegaard, Kaja VerfasserIn aut Grotefeld, Eric VerfasserIn aut Bouquet, Cyril VerfasserIn aut |
| spellingShingle | Meister, Alyson Oppegaard, Kaja Grotefeld, Eric Bouquet, Cyril Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being Hallucinogenic drugs Therapeutic use Hallucinogènes ; Emploi en thérapeutique Hallucinogenic drugs ; Therapeutic use |
| title | Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being |
| title_auth | Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being |
| title_exact_search | Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being |
| title_full | Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being Alyson Meister, Kaja Oppegaard, Eric Grotefeld, Cyril Bouquet |
| title_fullStr | Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being Alyson Meister, Kaja Oppegaard, Eric Grotefeld, Cyril Bouquet |
| title_full_unstemmed | Could psychedelics open new doors for science and business? psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being Alyson Meister, Kaja Oppegaard, Eric Grotefeld, Cyril Bouquet |
| title_short | Could psychedelics open new doors for science and business? |
| title_sort | could psychedelics open new doors for science and business psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well being |
| title_sub | psychedelic medicines and therapies are becoming more mainstream and may offer innovative solutions in an era of declining mental health and well-being |
| topic | Hallucinogenic drugs Therapeutic use Hallucinogènes ; Emploi en thérapeutique Hallucinogenic drugs ; Therapeutic use |
| topic_facet | Hallucinogenic drugs Therapeutic use Hallucinogènes ; Emploi en thérapeutique Hallucinogenic drugs ; Therapeutic use |
| work_keys_str_mv | AT meisteralyson couldpsychedelicsopennewdoorsforscienceandbusinesspsychedelicmedicinesandtherapiesarebecomingmoremainstreamandmayofferinnovativesolutionsinaneraofdecliningmentalhealthandwellbeing AT oppegaardkaja couldpsychedelicsopennewdoorsforscienceandbusinesspsychedelicmedicinesandtherapiesarebecomingmoremainstreamandmayofferinnovativesolutionsinaneraofdecliningmentalhealthandwellbeing AT grotefelderic couldpsychedelicsopennewdoorsforscienceandbusinesspsychedelicmedicinesandtherapiesarebecomingmoremainstreamandmayofferinnovativesolutionsinaneraofdecliningmentalhealthandwellbeing AT bouquetcyril couldpsychedelicsopennewdoorsforscienceandbusinesspsychedelicmedicinesandtherapiesarebecomingmoremainstreamandmayofferinnovativesolutionsinaneraofdecliningmentalhealthandwellbeing |